PRESCRIPTION HAIR LOSS AND HAIR REMOVAL DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Prescription Hair Loss and Hair Removal Drugs Market, By Drug Type (Hair Loss Medications, Oral Contraceptive Pills, Hair Removal Medications), By Gender (Male and Female), By Application (Chronic Hair Loss and Acute Hair Loss), By Route of Administration (Topical, Oral, Injectable), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

In December 2023, Aclaris Therapeutics entered into a license agreement with Sun Pharmaceutical Industries, allowing Aclaris to access Sun Pharma's JAK inhibitor and other isotopic forms of ruxolitinib for the treatment of androgenetic alopecia and alopecia areata. This agreement is expected to drive innovation in hair loss treatments.
In June 2023, Pfizer Inc. announced the approval of LITFULO by the U.S. FDA, marking it as the first treatment approved for adolescents (12+) to treat severe alopecia areata. This approval expands treatment options for younger patients suffering from this condition.
In July 2023, REVIAN Inc. announced that the Revian Red Hair Growth System will undergo a second study, anticipated to be an effective treatment option for Central Centrifugal Cicatricial Alopecia (CCCA). This development highlights ongoing research and innovation in hair loss treatments.
In June 2023, Cipla Limited expanded its alopecia treatment portfolio by launching a generic formulation of minoxidil as a topical hair loss treatment. This move is aimed at increasing accessibility to effective hair loss solutions.
In January 2023, Sun Pharmaceuticals Industries Ltd announced the acquisition of Concert Pharmaceuticals, a biotechnology company specializing in treatments for alopecia areata. This acquisition aims to enhance Sun Pharma's portfolio in the hair loss treatment sector.